Palisade Bio, Inc. (PALI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Palisade Bio, Inc. ( PALI ) Morgan Stanley 24th Annual Global Healthcare Conference September 16, 2026 10:00 AM EDT Company Participants J. Finley - CEO, CFO & Director Mitchell Jones - President & Chief Medical Officer Conference Call Participants Frank Tang - Morgan Stanley Presentation Frank Tang Morgan Stanley Good morning, everyone. My name is Frank Tang, and I'm with the Investment and Banking Division at Morgan Stanley. Thank you all for joining us for the fireside chat with Palisade Bio. I'm joined today by CEO J.D. Finley; and President and Chief Medical Officer Mitch Jones. Welcome. Question-and-Answer Session Frank Tang Morgan Stanley For those who are not as familiar with Palisade Bio, could you give us an overview of where the company sits today, including a description. And give us an overview of PALI-2108, the thesis behind the once-daily gut-targeted, locally-activated oral PDE4 inhibitor project? J. Finley CEO, CFO & Director Sure, thanks, Frank. So the PALI-2108 is a drug that we acquired from a Canadian company, Giiant Pharma, out of Montreal. That company was founded by some medicinal chemists from the Merck Frosst Labs in Montreal. When they closed that down in 2010, these guys took some of the science with them and developed this PDE4 prodrug formulation. It was in preclinical status when we acquired it. We've taken it through, completed the preclinical and the Phase I, and we are now about to start a Phase II study in both ulcerative colitis and Crohn's. And one of the interesting things about the design of the molecule, it was designed as a prodrug, which was intended to be specifically engineered for IBD. And they've seen the efficacy with other PDE4s in the IBD space, but the problem has typically been the adverse events and the prodrug formulation, which we can get into a little bit further, really avoids some of those additional AEs that you normally would see with